KR101877401B1 - Composition for anti-obesity and skin-whitening comprising Vitex rotundifolia extract as effective component - Google Patents

Abstract

The extract or extract of Porphyra wood according to the present invention is obtained by solubilizing insoluble fibrous components through enzymatic treatment and ultrahigh pressure homogenization treatment to enhance extraction yield and physiological activity, Since the whitening composition effectively inhibits fat accumulation and effectively inhibits melanin production, the composition for anti-obesity and skin whitening using the Porphyra species extract of the present invention can be used for the obesity-related industries, functional cosmetics for skin whitening and skin pigmentation diseases Can be usefully used as a therapeutic agent for a health functional food or a skin pigmentation disease which can prevent or improve.

Description

TECHNICAL FIELD The present invention relates to a composition for anti-obesity and skin whitening comprising an extract of Panax notoginseng as an active ingredient and a skin whitening composition comprising Vitex rotundifolia extract as effective component.

The present invention relates to a composition for anti-obesity and skin whitening comprising an extract of Panax notoginseng as an active ingredient.

Obesity is defined as the excess accumulation of fat in the body, and according to national health statistics, the prevalence of obesity is increasing from 26.0% in 1998 to 31.4% in 2011. Obesity has been found to be associated with complications of various adult diseases. For example, obesity patients have been reported to have a higher mortality rate compared to those who have normal weight, twice as much in the case of cirrhosis, 1.6 times in the case of cerebrovascular disease and 1.8 times in the case of coronary artery disease.

Currently, obesity treatment methods such as diet, exercise and drug therapy are being tried. Among them, the therapeutic agents for obesity, which are used as drug therapy, include appetite control, obstruction of digestion and absorption of fat, increase of energy consumption, , But there are various side effects.

Xenical (Roche) inhibits fat absorption by inducing lipase inhibition in the pancreas and digestive system, but has a low weight loss effect of only 2 to 3% and is accompanied by frequent side effects such as diarrhea and fatty liver.

In addition, reductil (Abbott) inhibits appetite by inhibiting the reuptake of serotonin and noradrenaline, thereby reducing body weight by 5 ~ 10%. However, there are side effects of cardiovascular diseases such as stroke and myocardial infarction, The EMA and the US Food and Drug Administration (FDA) withdrew from the market with prescription, suspension and voluntary recall recommendations, and were discontinued by the Food and Drug Administration in October 2010 in Korea.

In addition, many of the products developed as anti-obesity drugs are prohibited from selling due to serious side effects. For example, aminophylline has been reported to have widespread adverse effects on the mental nervous system, circulatory system, and digestive system, despite its excellent body fat degradation, and penfluramine, dexfenfluramine, topiramime, or ephedrine, Sales were banned. As such, the value of natural products and medicines with anti-obesity effect is newly emerging due to the limitations of western medicine due to side effects of synthetic drugs and overcoming of chronic diseases.

The color of human skin, hair and eyes is determined by melanin, carotene and hemoglobin. In particular, melanin is the most important factor in determining skin color, and skin color is determined by the amount and nature of melanin and its degree of distribution. The pigment of human skin or hair protects skin and hair from the harmful effects of sunlight, especially ultraviolet rays. For example, people who lack these pigments are very susceptible to sunlight and are susceptible to burns, and the likelihood of developing skin cancer at a young age is high. Short wavelength ultraviolet (290-320 nm) and carcinogens are known to form harmful radicals, such as oxygen radicals, in the skin, and these oxygen radicals attack skin cells and aging skin.

The main function of melanin is to remove these harmful radicals to protect the skin from damage caused by it. Thus, a high amount of melanin means that it has an effective countermeasure to protect the skin from physical or chemical toxicants. Factors that promote the production of melanin include sunlight (ultraviolet rays) as well as estrogen or prostaglandine.

On the other hand, melanin is produced by ultraviolet rays in melanocytes after tyrosinase is converted into dopa (DOPA) and dopachrome by an enzyme called tyrosinase and then subjected to complex oxidation and condensation reaction. At this time, melanin produced is transferred to skin cells, and melanin is lost with epidermal detachment and disappearing circulation.

This process of melanin production is a naturally occurring phenomenon and does not result in overproduction of melanin in normal human skin. However, when the skin responds to external stimuli such as ultraviolet rays, environmental pollution or stress, melanin is overproduced. When melanin is produced in such a way that it is not released to the outside of the skin and remains in the skin, pigmentation occurs and appears as spots and freckles.

Of these external stimuli, ultraviolet light is the largest source of melanin biosynthesis stimuli, which can affect various processes related to melanin production. That is, ultraviolet rays act as an important factor for inducing melanin overgrowth through promoting activity of melanocyte, a melanocyte-producing cell, promoting secretion of melanin biosynthesis stimulating hormone, promoting melanin oxidation, or stimulating tyrosinase activity.

In the prior art, ascorbic acid is known as a whitening substance, but its phase stability is poor in the formulation, and the activity of the active ingredient is deteriorated over time. Hydroquinone is excellent in its effect, but as a carcinogenic substance, There is a limit to the use of In addition, kojic acid is excellent in whitening effect due to its excellent tyrosinase inhibiting ability, but has a problem that phase stability in a formulation is inferior such as ascorbic acid.

Thus, research on whitening substances which are harmless to humans and excellent in formulation stability has been carried out for a long time, and it is expected that natural whitening substances which are harmless to human body and excellent in formulation stability can be developed by searching melanin synthesis inhibiting function from natural products have.

On the other hand, Vitex rotundifolia is a kind of marine algae distributed along coasts in Korea and Japan. These plants live in a unique environment in which sea water and fresh water are mixed, and by developing appropriate adaptation works, It is attracting attention as a new material resource. It is characterized by the lips of purple flowers and the whole grayish white hairy hair. In one room, the fruit is called 子 子, and it is used for the treatment of diseases such as headache, use. It has been confirmed that the extracts of Phellinus linteus have anticancer activity against HT-29 human colon cancer cells, and the secondary metabolites of flavonoids and terpenoids have been isolated by a number of studies, and their physiological activity effects have also been reported .

Korean Patent Registration No. 1125778 discloses an anticancer composition containing a flavonoid compound derived from Porphyra yezoensis. Korean Patent Registration No. 1127929 discloses an anti-atopic cosmetic composition containing an extract of Pseudoptera as an active ingredient However, the composition for anti-obesity and skin whitening, which comprises the extract of Porphyra species of the present invention as an active ingredient, has not been disclosed.

The present invention provides a composition for anti-obesity and skin whitening comprising an extract of Porphyra species as an active ingredient, wherein the effective ingredient, The present inventors have completed the present invention by confirming that not only the extraction yield was improved but also the fat accumulation inhibitory ability and melanin production inhibiting ability of Porphyra species were enhanced.

In order to accomplish the above object, the present invention provides a method for producing an extract of Porphyra woody, comprising the step of adding an enzyme to a mixture of Pseudomonas sp. Powder with water and hydrolyzing the mixture, Or a pharmaceutically acceptable salt thereof.

The present invention also provides a health functional food composition for preventing or ameliorating obesity, which comprises the Porphyra species as an active ingredient.

The present invention also provides a cosmetic composition for skin whitening comprising the above-described Pseudomonas sp. Extract as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing or treating a melanin pigment hyperproliferative disorder, comprising the Porphyra species as an active ingredient.

The present invention also provides a health functional food composition for preventing or ameliorating melanin pigment hyperpigmentation diseases comprising the Porphyra species as an active ingredient.

The extract or extract of Porphyra wood according to the present invention is obtained by solubilizing insoluble fibrous components through enzymatic treatment and ultrahigh pressure homogenization treatment to enhance extraction yield and physiological activity, Since the whitening composition effectively inhibits the fat accumulation and effectively inhibits melanin production, the composition for anti-obesity and skin whitening using the botanical extracts of the present invention can be used as a therapeutic agent for the treatment or prevention of obesity and a health functional food for prevention or improvement of obesity Functional cosmetics for skin whitening and skin color pigmentation diseases which can prevent or ameliorate skin pigmentation diseases.

FIG. 1 shows the results of confirming the inhibitory effect of the extract of Pseudomonas sp.
FIG. 2 shows the results of confirming the fat accumulation inhibitory activity of the Pseudomonas sp.
FIG. 3 shows the results of confirming the melanin biosynthesis inhibitory activity of the Pseudomonas sp.
FIG. 4 shows the results of confirming the melanin biosynthesis inhibitory activity of the Pseudomonas sp.

The present invention provides a pharmaceutical composition for preventing or treating obesity, comprising an extract of Porphyra species prepared by a method comprising the steps of:

(a) drying and then pulverizing the Pseudomonas sp.

(b) adding an enzyme to the mixture of pure non-wood powder prepared in step (a) and hydrolyzing the mixture;

(c) treating the hydrolyzate of step (b) with 100% ethanol; And

(d) homogenizing the ethanol-treated hydrolyzate of step (c) by ultra-high pressure.

In the method for producing the Porphyra species of the present invention, the Porphyra species of the step (a) is preferably selected from leaves, fruits and mixtures thereof, but is not limited thereto.

The enzyme of step (b) is preferably selected from the group consisting of Viscozyme, Pectinex and mixtures thereof, but is not limited thereto.

The viscozyme is a commercial enzyme which is derived from Aspergillus aculeatus arabinase, Cellulase, Beta-glucanase, hemicellulase, , And xylanase. ≪ / RTI >

Pectinex is a commercial enzyme and is a complex enzyme containing polygalacturonase derived from Aspergillus aculeatus .

According to one embodiment of the present invention, the leaves and fruits of Porphyra species can be improved in yield and fat accumulation inhibitory effect of each extract of Pseudomonas sp.

In step (b) of the present invention, the step (b) is preferably carried out by adding 10 to 14 times (v / w) water adjusted to pH 3.5 to 5.5 to Pseudomonas sp. The mixture can be hydrolyzed at 30 to 60 ° C for 1 to 12 hours after the addition of Pectinex, more preferably 12 to 12 times (v / w) of water adjusted to pH 4.5 to the pectin powder After adding Pectinex, it can be hydrolyzed at 50 ° C for 8 to 12 hours.

The hydrolysis of the Pseudomonas sp. Powder under the above conditions improves the extraction yield and solubility of the active material by solubilizing the insoluble matter of the Pseudomonas sp. By low molecular weight or rearrangement through molecular rearrangement, there was.

In addition, in the method for producing an extract of Porphyra woody of the present invention, the ethanol treatment in step (c) preferably comprises adding 6 to 8 times (v / v) 100% ethanol to the hydrolyzate at 20 to 30 ° C (V / v) of 100% ethanol is added to the hydrolyzate, and the mixture is stirred at 20 to 30 ° C for 2 hours at 180 rpm.

In addition, in the method for producing the Porphyra species of the present invention, the step of centrifuging the ethanol-treated hydrolyzate and recovering the supernatant may be further included.

In addition, in the method for producing Porphyra species of the present invention, the ultra-high pressure homogenization of step (d) can be homogenized at 100 to 120 MPa pressure, more preferably at 110 MPa pressure.

The process for preparing the extract of Porphyra discus according to the present invention is more preferably

(a) drying the leaves and the fruit of the Pseudomonas sp.

(b) Pectinex is added to a mixture obtained by adding 10 to 14 times (v / w) of water adjusted to pH 3.5 to 5.5 to the pure non-tree powder prepared in the step (a) Lt; 0 > C for 1 to 12 hours;

(c) adding 6 to 8 times (v / v) 100% ethanol to the hydrolyzate of step (b) and treating the mixture at 20 to 30 ° C for 1 to 3 hours; And

(d) homogenizing the ethanol-treated hydrolyzate of step (c) under ultra-high pressure at a pressure of 100 to 120 MPa.

The Pseudomonas sp. Extract is characterized by inhibiting fat accumulation.

The pharmaceutical composition preferably further comprises a carrier, an excipient, or a diluent in addition to the Porphyra woody extract, but is not limited thereto.

The pharmaceutical composition comprising the Porphyra species extract of the present invention as an active ingredient may be various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of suppositories include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and it is preferable to select the intravenous, intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine or intracerebral injection methods during parenteral administration, But is not limited to.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

The dosage of the pharmaceutical composition of the present invention may be varied depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.

In addition, the present invention provides a health functional food composition for preventing or ameliorating obesity, which comprises an extract of Porphyra species prepared by a method comprising the steps of:

(a) drying and then pulverizing the Pseudomonas sp.

(b) adding an enzyme to the mixture of pure non-wood powder prepared in step (a) and hydrolyzing the mixture;

(c) treating the hydrolyzate of step (b) with 100% ethanol; And

(d) homogenizing the ethanol-treated hydrolyzate of step (c) by ultra-high pressure.

The effective ingredient of the health functional food composition for preventing or ameliorating obesity of the present invention is as described above.

The health functional food composition for preventing or ameliorating obesity containing the Porphyra species extract of the present invention as an active ingredient may be prepared from any one selected from a beverage, a ring, a tablet, a capsule, and a powder, May be prepared by adding to the components of the food, and may be suitably prepared according to a conventional method.

Examples of foods to which the health functional food composition of the present invention can be added include meat products, sausages, breads, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, Beverage, tea, drink, alcoholic beverage, and vitamin complex, and includes all the health foods in the ordinary sense.

The health functional foods include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alkynic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.

The health functional food composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tau Martin and stevia extract, synthetic sweetening agents such as saccharin and aspartic acid, and the like can be used.

The present invention also provides a cosmetic composition for skin whitening comprising, as an active ingredient, an extract of Panax notoginseng produced by a method comprising the steps of:

(a) drying and then pulverizing the Pseudomonas sp.

(b) adding an enzyme to the mixture of pure non-wood powder prepared in step (a) and hydrolyzing the mixture;

(c) treating the hydrolyzate of step (b) with 100% ethanol; And

(d) homogenizing the ethanol-treated hydrolyzate of step (c) by ultra-high pressure.

The effective ingredient of the cosmetic composition for skin whitening of the present invention is as described above.

According to one embodiment of the present invention, the yield of Porphyra japonica extract was increased and the melanin synthesis was inhibited by applying ultrafast pressure homogenization after treatment with viscose or pectinex.

On the other hand, the whitening effect refers to an effect to improve or prevent glaring skin, spots, freckles, and dark circles caused by various factors such as exposure to ultraviolet rays, change in hormone balance, genetic program, Or an effect of maintaining a beautiful skin with a sense of transparency and an effect of reducing the dullness of the skin to increase gloss and tautness. In general, it is known that the skin, spots, freckles, and dark circles of the skin, stamens, freckles and dark circles are stimulated by melanocytes due to stimulation by ultraviolet rays or changes in hormone balance, and melanin pigment is deposited on the skin. Therefore, if the production of melanin can be inhibited, it is possible to prevent or improve gross skin, spots, freckles and dark circles.

The cosmetic composition for skin whitening may be a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleansing oil, a powder foundation, an emulsion foundation, a wax foundation and a spray , But the present invention is not limited thereto. The cosmetic composition comprising each of these formulations may contain various bases and additives necessary for formulation of the formulation, and the kinds and amounts of these ingredients can be easily selected by those skilled in the art.

The cosmetic composition of the present invention may contain, in addition to the active ingredient, at least one skin whitening active ingredient exhibiting the same or similar functions. Skin whitening active ingredients include kojic acid and its derivatives, arbutin, ascorbic acid and its derivatives, hydroquinone and its derivatives, resorcinol, cycloalkanone, methylenedioxyphenylalkanol, 2,7-dinitroindazole or Plant extracts such as mandarin orange extract, rice extract, licorice extract, and the like, but are not limited thereto.

When the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal fiber, a plant fiber, a wax, a paraffin, a starch, a tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Etc. may be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, Propellants such as carbon, propane-butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or an emulsion, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the cosmetic composition of the present invention is a cleansing agent containing an interfacial active agent, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyltaurate, sarcosinate , Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative or ethoxylated glycerol fatty acid ester.

The cosmetic composition of the present invention may further contain an excipient including a fluorescent substance, a fungicide, a hygroscopic substance, a moisturizer, a fragrance, a fragrance carrier, a protein, a solubilizer, a sugar derivative, a sunscreen, a vitamin, .

In addition, the present invention provides a pharmaceutical composition for preventing or treating melanin pigment hyperproliferative disorder, which comprises as an active ingredient an extract of Porphyra species prepared by a method comprising the steps of:

(a) drying and then pulverizing the Pseudomonas sp.

(b) adding an enzyme to the mixture of pure non-wood powder prepared in step (a) and hydrolyzing the mixture;

(c) treating the hydrolyzate of step (b) with 100% ethanol; And

(d) homogenizing the ethanol-treated hydrolyzate of step (c) by ultra-high pressure.

The method for producing the Pseudomonas sieboldii extract, which is an active ingredient of the pharmaceutical composition for preventing or treating melanin pigment hyperproliferative disease of the present invention, is as described above.

The pharmaceutical composition for preventing or treating melanin pigment hyperproliferative disorder, which comprises the Porphyra species extract of the present invention as an active ingredient, can be prepared according to the manufacturing method of a person skilled in the art, as described above.

The present invention also provides a health functional food composition for preventing or ameliorating hyperpigmentation of melanin pigment comprising an extract of Porphyra species prepared by a method comprising the steps of:

(a) drying and then pulverizing the Pseudomonas sp.

(b) adding an enzyme to the mixture of pure non-wood powder prepared in step (a) and hydrolyzing the mixture;

(c) treating the hydrolyzate of step (b) with 100% ethanol; And

(d) homogenizing the ethanol-treated hydrolyzate of step (c) by ultra-high pressure.

The method for preparing the Porphyra woody extract, which is an effective ingredient of the health functional food composition for preventing or ameliorating the melanin pigment hyperpigmentation disease of the present invention, is as described above.

The health functional food composition for prevention or amelioration of the melanin pigment hyperproliferative disorder comprising the Porphyra species extract of the present invention as an active ingredient can be prepared according to the manufacturing method of the person skilled in the art, as described above.

Hereinafter, the present invention will be described in more detail with reference to Preparation Examples and Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.

Manufacturing example  1. Manufacture of Punggi extract

In order to observe the extraction yield and compositional composition of the extracts according to the type of enzymes and the presence or absence of ultrahigh pressure homogenization, the extracts according to enzyme type, presence / absence of ultrahigh pressure homogenization and enzymatic treatment + hyperbaric homogenization were prepared as follows .

(1) Enzyme treatment

30 ml of distilled water adjusted to pH 4.5 and 2.5 g of viscozyme and pectinex (enzymes) were added to each 50 g / ml and 500 unit / Lt; 0 > C and 37 [deg.] C at 180 rpm. The enzyme was treated at the optimum time (10 hours and 2 hours), and then 70 ml of 100% ethanol was added. The mixture was extracted at 180 rpm for 2 hours at room temperature and then centrifuged at 12,000 rpm for 15 minutes.

(2) Ultra high pressure homogenization treatment

30 ml of distilled water adjusted to pH 4.5 and 70 ml of 100% ethanol were added to 2.5 g of the dried or pulverized leaves or fruit of the plant, and the mixture was centrifuged at 12,000 rpm for 15 minutes and filtered to prepare a filtrate And then passed through an orifice tube twice at a pressure of 110 MPa.

(3) Enzyme treatment and high pressure homogenization parallel treatment

30 ml of distilled water adjusted to pH 4.5 and 2.5 g of viscozyme and pectinex (enzymes) were added to each 50 g / ml and 500 unit / Lt; 0 > C and 37 [deg.] C at 180 rpm. The enzymes were treated at optimal times (10 hours and 2 hours), and 70 ml of 100% ethanol was added. The mixture was extracted at 180 rpm for 2 hours at room temperature (25 ° C), centrifuged at 12,000 rpm for 15 minutes, And then passed through an orifice tube twice under a pressure of 110 MPa.

Example  1. Identification of Extraction Yield of Pumpkin

Changes in the extraction yields of various enzymes and ultrahigh pressure treatments were measured for the functional materials using the extracts of.

As a result, the extraction yield was improved in the enzyme treatment and the extraction yield was improved even in the case of ultra - high pressure homogenization, compared with that of the pure white powder. In the case of using Pectinet (Pectinet), the ultimate pressure homogenization treatment was increased by 159.86% in the case of using Porphyntonia japonica. And high extraction yield (Table 1).

Extraction yield (%) of Pseudomonas sp. Leaves and fruits by enzyme treatment and ultrahigh pressure homogenization treatment Pure wood
Raw material Treatment condition Extraction yield (%) Non-treatment group preparation
Growth rate (%) leaf




Untreated group 27.37 Enzyme V (viscozyme) 35.68 30.36 Enzyme P (pectinex) 40.14 46.66 Ultrahigh pressure homogeneity 32.23 17.76 Enzyme V + Ultra High Pressure Homogeneity 35.14 28.39 Enzyme P + ultrahigh pressure homogeneity 40.48 47.90 Fruit




Untreated group 4.21 Enzyme V (viscozyme) 5.48 30.17 Enzyme P (pectinex) 8.38 99.05 Ultrahigh pressure homogeneity 7.37 75.06 Enzyme V + Ultra High Pressure Homogeneity 8.17 94.06 Enzyme P + ultrahigh pressure homogeneity 10.94 159.86

Example  2. Pure bitterwood extract Anti-obesity  Check efficacy

To determine the degree of differentiation of 3T3-L1 cells, a lipogenic precursor cell line, the cells were stained with oil red-O. In order to observe the differentiated cells, the cultured cells were fixed with 10% formalin / PBS for 5 minutes at room temperature, and then the cells were washed once with 60% isopropanol and dried. Then the oil red-oak was added for 30 min, stained and washed 4 times with distilled water, while the fat droplets were observed under a microscope with distilled water. After observation, 99% isopropanol was added and dissolved at 180 rpm for 10 minutes and then measured at 520 nm.

In order to measure the inhibitory effect of 3T3-L1 cells on the lipid accumulation of Phellinus linteus extracts by the enzymatic treatment and the high-pressure homogenization process according to the present invention, they were diluted with the same dilution factor, and as a result, they were subjected to enzymatic treatment and ultrahigh pressure homogenization In particular, treatment with Pectinex and Pectinex in the treatment of P. vivax leaf extracts showed 22% and 48%, respectively, compared to MDI treatment (50% and 58%, respectively), compared to the MDI-treated group (Fig. 1), while the Pectinex treatment group and the Pectinex treated group treated with the ultra high pressure homogenate (Fig. 2). ≪ tb >< TABLE >

Example  3. Identification of the whitening activity of the extract

In order to confirm the whitening activity of Phellodendron tamariscina extract, the amount of melanin biosynthesis was measured. B16F10 cells were inoculated in 12 wells at a density of 1 × 10 ⁵ cells / ml and cultured. After 24 hours, thallus extract (50, 100, 200 μg / ml) and arbutin (100 μg / ml) Lt; / RTI > for 48 hours. After the treatment, the cells were washed twice with PBS (phosphate buffered saline) and centrifuged to make cell precipitate. 200 μl of 1 N NaOH solution containing 10% DMSO (dimethyl sulfoxide) was added and dissolved at 60 ° C for 1 hour. Absorbance was measured at 405 nm.

In order to measure the amount of melanin biosynthesis of Pseudomonas sp. Leaves and fruit extracts through enzymatic treatment and ultrahigh pressure homogenization, all of them were diluted to the same dilution level and showed the same efficacy as arbutin (Ar) In the extracts obtained by the combination of ultra high pressure homogenization treatment on the leaves of the non - leaf blade, the high - pressure homogenization treatment on the extracts with the enzyme treatment and the high - pressure homogenization, and the high - It was confirmed that melanin production was reduced compared with the extract of Phellinus linteus without ultrahigh pressure extraction (FIG. 3 and FIG. 4).

Claims (10)

A pharmaceutical composition for preventing or treating obesity comprising an extract of Pseudomonas sieboldii leaf extract prepared by a method comprising the steps of:
(a) a step of drying and then pulverizing the Pseudomonas sp.
(b) Pectinex is added to a mixture of 10 to 14 times (v / w) of water adjusted to pH 3.5 to 5.5 in the pure alfalfa leaf powder prepared in the step (a) Hydrolyzing at 60 DEG C for 1 to 12 hours;
(c) adding 6 to 8 times (v / v) 100% ethanol to the hydrolyzate of step (b) and treating the mixture at 20 to 30 ° C for 1 to 3 hours; And
(d) homogenizing the ethanol-treated hydrolyzate obtained in step (c) under a pressure of 100 to 120 MPa. delete delete delete delete The pharmaceutical composition for preventing or treating obesity according to claim 1, wherein the Pseudomonas sp. Leaves extract inhibits fat accumulation. A health functional food composition for preventing or ameliorating obesity comprising an extract of Pseudomonas sieboldii leaf extract prepared by a method comprising the steps of:
(a) a step of drying and then pulverizing the Pseudomonas sp.
(b) Pectinex is added to a mixture of 10 to 14 times (v / w) of water adjusted to pH 3.5 to 5.5 in the pure alfalfa leaf powder prepared in the step (a) Hydrolyzing at 60 DEG C for 1 to 12 hours;
(c) adding 6 to 8 times (v / v) 100% ethanol to the hydrolyzate of step (b) and treating the mixture at 20 to 30 ° C for 1 to 3 hours; And
(d) homogenizing the ethanol-treated hydrolyzate obtained in step (c) under a pressure of 100 to 120 MPa. delete delete delete

Images